Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 10/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 9/20 | 0.46 |
| ▸ | IGF1R | P08069 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679543 | 1.00 | PIM1 (0.46) | PIM1PIM2IGF1RHPGDPTPN1 | |
| SCHEMBL679542 | 1.00 | PIM1 (0.46) | PIM1PIM2IGF1RHPGDPTPN1 | |
| SCHEMBL679031 | 0.98 | PIM1 (0.45) | PIM1PIM2IGF1RHPGDPTPN1 | |
| SCHEMBL679033 | 0.98 | PIM1 (0.45) | PIM1PIM2IGF1RHPGDPTPN1 | |
| SCHEMBL679774 | 0.98 | PIM1 (0.45) | PIM1PIM2IGF1RHPGDPTPN1 | |
| SCHEMBL679788 | 0.98 | PIM1 (0.45) | PIM1PIM2IGF1RHPGDPTPN1 | |
| SCHEMBL679833 | 0.98 | PIM1 (0.45) | PIM1PIM2IGF1RHPGDPTPN1 | |
| SCHEMBL678088 | 0.98 | PIM1 (0.45) | PIM1PIM2IGF1RHPGDPTPN1 | |
| SCHEMBL678089 | 0.98 | PIM1 (0.45) | PIM1PIM2IGF1RHPGDPTPN1 | |
| SCHEMBL679773 | 0.98 | PIM1 (0.45) | PIM1PIM2IGF1RHPGDPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2365969-B1 | Novel anti-biofilm agents | YISSUM RES DEV CO (IL) | 2017-03-22 | — | — | EP | disclosed |
| US-8865909-B2 | Anti-biofilm agents | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-21 | — | — | US | disclosed |
| US-20110281921-A1 | NOVEL ANTI-BIOFILM AGENTS | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2011-11-17 | — | — | US | disclosed |
| EP-2365969-A1 | Novel anti-biofilm agents | Yissum Research Development Company of The Hebrew University of Jerusalem (IL) | 2011-09-21 | — | — | EP | disclosed |
| WO-2010058402-A1 | NOVEL ANTI-BIOFILM AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281921-A1 | NOVEL ANTI-BIOFILM AGENTS | PYCARD, DNM2, MMP8 | PIM1 308/4885PIM2 200/4885IGF1R 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.